Announces funding via third-party allotment using stock acquisition rights. 345,000 units, total 2,415,000 yen, potential shares 34,500,000 shares, initial exercise price 57 yen, adjusted to 97% of closing price on each adjustment date with rounding up; minimum 29 yen. Acquired rights, exercise suspension period, and caps on allotted shares are designed to manage dilution and enable flexible fundraising.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4594","jir_company_name":"BrightPath Bio Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/4594-20260918-01.pdf","jir_short_summary":"Announces funding via third-party allotment using stock acquisition rights. 345,000 units, total 2,415,000 yen, potential shares 34,500,000 shares, initial exercise price 57 yen, adjusted to 97% of closing price on each adjustment date with rounding up; minimum 29 yen. Acquired rights, exercise suspension period, and caps on allotted shares are designed to manage dilution and enable flexible fundraising.","jir_summary":"### Overview of financing\nBrightPath Bio resolved to issue the 21st stock acquisition rights through third-party allotment. Allottee is Phillip Capital Securities Inc., 345,000 units, total 2,415,000 yen, implied underlying shares 34,500,000 shares. Exercise price initially 57 yen, subsequently adjusted on each adjustment date to 97% of the market closing price with rounding up, with a lower bound of 29 yen. The design includes terms such as acquisition provisions, exercise suspension period, and fixed maximum number of issuable shares to balance dilution control with funding flexibility.\n\n### Use of funds and outlook\nFunds are to be used primarily for BP2202 US Phase I clinical trial costs, new pipeline development, and other operating funds. Timing is assumed from June 2027 to September 2028. Depending on stock price trends, the amount and timing of funding may vary, and actual expenditures will be determined according to exercise status.","jir_financial_highlights":"Amount raised: 1,952,915,000 yen (Estimated net proceeds)\nTotal number of allocations: 345,000 units (Unknown)\nTotal issued amount: 2,415,000 yen (Fixed)","jir_category":"","jir_hashtags":"#BrightPathBio, #StockAcquisitionRight, #fundraising, #BP2202","jir_key_figures":"345,000 units: total number of stock acquisition rights\n34,500,000 shares: target shares (100 shares per right)\n1,952,915,000 yen: estimated net proceeds","jir_meta_title":"BrightPath Bio: Notice of Issuance of Stock Acquisition Rights through Third-Party Allotment | 2026-09-18","jir_meta_description":"BrightPath Bio announces the issuance of the 21st stock acquisition rights through third-party allotment. 345,000 units, total 2,415,000 yen, underlying shares 34,500,000, with exercise price adjustment provisions. Funds to be used for US Phase I clinical trial costs and related purposes.","jir_og_title":"BrightPath Bio: Fundraising via Stock Acquisition Rights Issuance | 2026-09-18","jir_og_description":"Announcement of fundraising using stock acquisition rights. Exercise price starts at 57 yen with adjustments on each amendment date. Funds to be used for BP2202 US clinical trial costs and related purposes.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59787,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-115414","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n